'For quarter ending June 2024, consolidated Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 5.96% to Rs 12652.75 crore compared to quarter ended June 2023. Operating profit margin has jumped from 27.90% to 28.51%, leading to 8.28% rise in operating profit to Rs 3,607.62 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.81% to 12.42%. Purchase of finished goods cost rose from 5.80% to 7.96%. Employee cost decreased from 20.50% to 19.59%. Other expenses rose from 29.44% to 31.24%.
Other income rose 160.49% to Rs 532.55 crore. PBIDT rose 17.08% to Rs 4140.17 crore. Provision for interest fell 23.91% to Rs 61.54 crore.
PBDT rose 18.04% to Rs 4078.63 crore. Provision for depreciation rose 0.58% to Rs 655.13 crore.
Profit before tax grew 22.09% to Rs 3,423.50 c...
Pleaselogin & subscribe to view the full report.
More Reports
-
Revenue up 11% YoY to Rs 33562.9 crore in Q2FY2025
-
(18-Nov-2024)
Bharat Forge
-
-
|
|